Ambros Therapeutics

Executive Summary

Ambros Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for diseases with high unmet medical need. Its lead program targets complex regional pain syndrome type 1 (CRPS-1), a rare and debilitating pain condition triggered by trauma. The company is currently in Phase 3 development, aiming to address the severe, unrelenting pain and functional loss experienced by patients. With no approved therapies for CRPS-1, Ambros has the potential to fill a significant therapeutic gap. The upcoming Phase 3 data readout will be critical for establishing efficacy and safety, and if positive, could position Ambros for regulatory filing and commercialization. The company's focus on a niche rare disease with high unmet need provides a clear path to market, though execution risk remains.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 top-line data readout for CRPS-160% success
• TBDPre-IND or IND filing for a new indication30% success
• H1 2027Partnership or licensing deal for CRPS-1 program40% success